Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS and ImClone Systems market cancer drug; concluded

Executive Summary

Bristol-Myers Squibb licensed US, Canadian, and some Japanese co-promotion rights to ImClone Systems' lead cancer drug, IMC-C225, a monoclonal antibody designed to target and block the epidermal growth factor receptor on which certain solid tumors depend for their growth.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register